News from janssen research A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 06, 2015, 10:00 ET

New Data Show Initial Use of Canagliflozin in Combination with Metformin Extended Release Significantly Improves A1C Levels in Adults with Type 2 Diabetes

 Janssen Research & Development, LLC (Janssen) today announced results of a phase 3, randomized study showing that the use of initial...

Jun 05, 2015, 11:50 ET

Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma

Janssen Research & Development, LLC (Janssen) has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to...

Jun 01, 2015, 17:00 ET

Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma

 Janssen Research & Development, LLC (Janssen) announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant...

May 30, 2015, 07:32 ET

Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia

 Data from the Phase 3 CLL3001 (HELIOS) trial demonstrated that the combination of ibrutinib (IMBRUVICA®) plus bendamustine and rituximab...

May 30, 2015, 07:31 ET

Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients

 Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent...

May 13, 2015, 17:09 ET

Janssen to Showcase Data from Five Compounds Including Daratumumab and IMBRUVICA at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Janssen Research & Development, LLC (Janssen) announced that data from five oncology treatments across the portfolio, including marketed and...

Mar 30, 2015, 08:00 ET

FDA Approves Label Update for ZYTIGA® to Include Statistically Significant Overall Survival Results in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer

 The U.S. Food and Drug Administration (FDA) has approved a label update for ZYTIGA® (abiraterone acetate) plus prednisone based on...

Mar 16, 2015, 15:07 ET

Phase 3 Study with IMBRUVICA® (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression

 Janssen Research & Development, LLC (Janssen) announced today that a pre-planned interim analysis of the Phase 3 HELIOS (CLL3001) study...

Feb 12, 2015, 06:15 ET

Janssen Sets A Course To Intercept Type 1 Diabetes Together With JDRF

Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it...

Feb 12, 2015, 06:00 ET

Janssen Launches Three New Research Platforms Focused on Redefining Healthcare

 Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today the...

Feb 03, 2015, 03:30 ET

U.S. FDA Grants Priority Review for YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review...

Jan 19, 2015, 10:00 ET

FDA Grants Priority Review for Three-Month Paliperidone Palmitate for the Treatment of Schizophrenia

Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for...

Dec 12, 2014, 12:15 ET

Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium

 Janssen Research & Development, LLC (Janssen) today announced the presentation of data at the San Antonio Breast Cancer Symposium...

Dec 08, 2014, 21:33 ET

IMBRUVICA® (ibrutinib) Long-term Follow-up Data in Patients Living with Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive at Two Years

 New data presented today at the American Society of Hematology (ASH) Annual Meeting in San Francisco, CA, suggest the current safety and...

Dec 08, 2014, 21:05 ET

IMBRUVICA® (ibrutinib) Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic Mutation

Results from the Phase 2 RESONATE™-17 (PCYC-1117) study show IMBRUVICA® (ibrutinib) was associated with an 82.6 percent...

Nov 24, 2014, 16:30 ET

Janssen Submits New Drug Application for YONDELIS® (trabectedin) to U.S. FDA for the Treatment of Patients with Advanced Soft Tissue Sarcoma

 Janssen Research & Development, LLC (Janssen) has submitted a New Drug Application (NDA) for YONDELIS® (trabectedin) to the U.S. Food...

Nov 19, 2014, 09:00 ET

Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate

Janssen Research & Development, LLC (Janssen) today announced the submission of a New Drug Application (NDA) for three-month atypical...

Nov 06, 2014, 09:54 ET

Janssen to Demonstrate Breadth of Oncology Portfolio with 41 Clinical Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting

Janssen Research & Development, LLC (Janssen) will present new data across more than eight disease areas at the 56th American Society of...

Nov 06, 2014, 03:00 ET

Janssen Collaborates for Continued Evaluation of Multidrug-Resistant Tuberculosis Treatment Regimens with SIRTURO® (bedaquiline)

Janssen Research & Development, LLC (Janssen) today announced a collaboration with the International Union Against Tuberculosis and Lung...

Oct 20, 2014, 08:05 ET

IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for...